An observational study in COVID-19, sponsored by Richmond Research Institute. Recruiting at 1 site in United Kingdom. Open to participants aged 5 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Richmond Research Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 340 studies in COVID-19 with a site in United Kingdom — 17 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · United Kingdom.
Among the 340 studies in COVID-19 with a site in United Kingdom, this one is the 33rd largest by planned enrollment of the 167 observational ones that give a count, is one of 192 that started in 2020, is one of 167 observational ones, reaches primary completion later than 30 of the 31 other live ones, and was the 72nd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →17 of the 340 studies in COVID-19 with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–50 · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 21 more countries
Ages 18+
Technical University of Munich · Sites in United Kingdom, Austria, Belgium and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 5 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
340 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 52 · Phase 3 66 · Phase 4 5
First in 2013; this study’s year is marked. 192 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 247 across the 172 interventional studies, 296 across the 167 observational. Of the 245 that completed or were terminated, 75 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 340 have an industry lead sponsor. The 10 most frequent:
Richmond Research Institute is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
Richmond Research Institute has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
5 of the studies in COVID-19 with a site in United Kingdom that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03188796Phase 3Medical University of GrazThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients | 2027-07 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04746183University of LiverpoolAGILE (Early Phase Platform Trial for COVID-19) | 2027-03-31 |
| NCT04863573Queen's University, BelfastCOVID-19 Antibody Responses In Cystic Fibrosis | 2027-08 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 340 studies in COVID-19 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results. Infection with coronavirus (SARS-CoV-2) is currently a worldwide pandemic and reliable testing for COVID-19 is crucial to understand who is infected and therefore a risk to others by spreading the infection. RRI are currently carrying out the following tests:
A. Using a membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens helps to assess whether an individual has previously had the virus and is potentially immune
B. Polymerase Chain Reaction (PCR) testing using an established method to check for active SARS-CoV-2 infections.
C. Quantification of anti-SARS-CoV-2 IgG and IgM antibodies in whole blood samples.
The above tests are being used by RRI to follow infections (PCR) and immunity (IgG) in their workforce, as well as their families (including children) and visitors to their site.
Collecting this data allows the gathering of epidemiological data on SARS-CoV-2 including incidence, prevalence, information on asymptomatic carriers and efficacy of vaccination. Furthermore, identifying individuals that are infected with SARS-CoV-2 has great potential to improve health outcomes by allowing infected individuals to seek the correct medical treatment as well as self-isolate and reduce transmission.
This is a screening study to measure symptomatic and asymptomatic carriage of SARS-CoV-2 in trial participants to help facilitate early detection of a second wave of SARS-CoV-2 infections. Specifically, this study aims to determine ; to assess the duration of immunity by assessing the number and speed at which trial participants were infected and cleared the virus with or without symptoms; and to determine the length of symptom onset in those with an active infection; levels of IgG antibodies by demographics (sex, age, ethnicity, and intensity of symptoms). Longitudinal assessment of antibody levels will additionally allow for assessment of the efficacy of any vaccines adminstered. This study also seeks to explore how many people are asymptomatic carriers. In addition, this study aims to help facilitate the development a quantitative laboratory reference test for antibodies (IgG).
By using multiple different tests, it can be determined if a person is currently infected with SARS-CoV-2 or whether they previously have been infected. This allows for the scanning of people with asymptomatic carriage of the virus, which is important to help reduce the spread of SARS-CoV-2 through contact with people unaware of infection.
Polymerase Chain Reaction (PCR) testing is routinely used to check for active SARS-CoV-2 infections. It measures whether viral RNA is present in an individual's system. All in-house PCR tests are verified by an independent laboratory to check for false positives.
Using a membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens helps to assess whether an individual has previously had the virus and is potentially immune. IgG and IgM detection components are separate allowing for differential detection of each antibody.
To this date, 20904 PCR tests and 6848 antibody tests have been carried out in 2328 individuals, providing some interim data. Of the 20904 PCR tests, 17635 (84%) were negative and 132 (1%) were negative. Of the 6848 antibody tests, 706 (10%) were positive for IgG only, 64 (1%) were positive for IgM only, and 351 (5%) were positive for both IgG and IgM. 5710 (83%) tests were negative.
Of those individuals with a positive PCR test, 53% reported fever during the previous two months and 75% reported a loss of taste during the previous two months.
Interim results are shown in the medRxiv papers below:
https://www.medrxiv.org/content/10.1101/2020.12.08.20245894v2
https://www.medrxiv.org/content/10.1101/2021.04.09.21255200v1
Participants are individuals who are screened upon entry to the Richmond Pharmacology unit. These individuals may be employees of Richmond Pharmacology, volunteers for other concurrent studies, or members of the public.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Male and female participants aged 5-70 years
Diagnostic Test: Membrane-based immunoassay kit · Diagnostic Test: Quantitative antibody Tests · Diagnostic Test: PCR Test
The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.
Also known as: Covid-19 Rapid Test Kit
Antibody titres will be measured from whole blood samples taken from volunteers.
Also known as: Antibody titre
PCR tests will be conducted on throat swabs taken from volunteers.
Identification of carriers of SARS-CoV-2
To identify trial participants who are symptomatic or asymptomatic carriers of SARS-CoV-2 by comparing the results of a blood finger stick test and reference laboratory tests to PCR testing for acute infection
Time frame: Through study completion, estimated 12 weeks
Determination of the duration of immunity to SARS-CoV-2
To determine the duration of immunity of trial participants previously infected with SARS-CoV-2, measure differences in IgG antibodies by demographics including sex, ethnicity and age and investigate correlation between IgG antibody levels and intensity of symptoms
Time frame: Through study completion, estimated 12 weeks
Development of a quantitative laboratory reference test for the measurement of SARS-CoV-2
Determination of the understanding of the quantity of IgG antibodies developed as a response to SARS-CoV-2 infection, and how these antibody levels decrease over time. Antibody titres will be measured in infected individuals, over multiple days and correlated with disease parameters. This will facilitate the development of a quantitative laboratory reference test for IgG antibodies
Time frame: Through study completion, estimated 12 weeks
Exploration of SARS-CoV-2 epidemiology
To help develop a quantitative laboratory reference test for antibodies (IgG) to gain an understanding of quantity of antibodies that people develop and how these decrease over time.
Time frame: Through study completion, estimated 12 weeks
Started Mar 2020 (actual). Primary completion is estimated for Dec 2028, 104 months after the start.
Of 134 industry-sponsored observational studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 19. This study's planned 104 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Richmond Research Institute